Clinical trialPhase 2Recruiting
Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer
Sintilimab Plus Chemotherapy and Radiotherapy for Patients With Inoperable Pancreatic Cancer: a Single-arm, Exploratory, Phase II Trial
- Outcome
- Ongoing
- Phase
- Phase 2
- Status
- Recruiting
- Study type
- Interventional
- Start
- 18 August 2023
- Expected end
- 18 December 2026
- Enrollment
- 25 participants
- Sites
- 1
- Primary outcomes
- PFS; AE
- Sponsor
- Other
- Results posted
- No
- Last update
- 15 October 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 20
- Registry-listed results paperPhase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with r… DOI 10.1016/j.ejca.2022.11.035↗
- BackgroundSotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic ana… DOI 10.1038/s41591-022-01829-9↗
- BackgroundRandomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refr… DOI 10.1200/jco.21.02511↗
- BackgroundA Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy… DOI 10.1097/sla.0000000000004669↗
- BackgroundRETRACTION: Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus… DOI 10.1016/s1470-2045(21)00286-2↗
- BackgroundRole of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
- BackgroundConventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreati… DOI 10.1002/cncr.32756↗
- BackgroundDHA-SBT-1214 Taxoid Nanoemulsion and Anti-PD-L1 Antibody Combination Therapy Enhances Antitumor Efficacy in a Syngeneic… DOI 10.1158/1535-7163.mct-18-1046↗
- BackgroundPhase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. DOI 10.1007/s10637-017-0525-1↗
- BackgroundStereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review. DOI 10.1002/cncr.30856↗
- BackgroundThe Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings. DOI 10.1016/j.soc.2017.01.012↗
- BackgroundOutcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy … DOI 10.1002/cncr.30706↗
- BackgroundEpidemiology of pancreatic cancer. DOI 10.3748/wjg.v22.i44.9694↗
- BackgroundEffect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled … DOI 10.1001/jama.2016.4324↗
- BackgroundSurgery for Localized Pancreatic Cancer: The Trend Is Not Improving. DOI 10.1097/mpa.0000000000000511↗
- BackgroundProjecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the Un… DOI 10.1158/0008-5472.can-14-0155↗
- BackgroundIncreased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. DOI 10.1056/nejmoa1304369↗
- BackgroundGemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern … DOI 10.1200/jco.2011.34.8904↗
- BackgroundFOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. DOI 10.1056/nejmoa1011923↗
- BackgroundPhase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) fol… DOI 10.1093/annonc/mdn281↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.